Efficacy and Safety of Denosumab vs Zoledronic Acid in OI Adults: A Prospective, Open-Label, Randomized Study.

Additionally, patients with OI with AD inheritance showed a trend toward higher percentage increases in aBMD at the LS (3.18 ± 4.38% vs 0.29 ± 5.19%), FN (2.25 ± 6.31% vs 0.56 ± 14.49%), and TH (3.15 ± 6.31% vs 2.59 ± 6.46%), along with a trend toward a greater decrease in β-CTX levels (−54.87 ± 27.56% vs −21.86 ± 48.38%) than those with non-AD inheritance, although this did not reach statistical significance.

also in 53,322 other papers

TBS showed an increasing trend by 1.39% and 2.70% in denosumab and zoledronic acid groups, respectively.

also in 63,971 other papers